DE69833225D1 - Verwendung von histamin um die blutkonzentration des histamins zu erhöhen - Google Patents

Verwendung von histamin um die blutkonzentration des histamins zu erhöhen

Info

Publication number
DE69833225D1
DE69833225D1 DE69833225T DE69833225T DE69833225D1 DE 69833225 D1 DE69833225 D1 DE 69833225D1 DE 69833225 T DE69833225 T DE 69833225T DE 69833225 T DE69833225 T DE 69833225T DE 69833225 D1 DE69833225 D1 DE 69833225D1
Authority
DE
Germany
Prior art keywords
histamine
methods
levels
natural killer
killer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69833225T
Other languages
English (en)
Other versions
DE69833225T2 (de
Inventor
Kristoffer Hellstrand
Svante Hermodsson
R Gehlsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Maxim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals Inc filed Critical Maxim Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69833225D1 publication Critical patent/DE69833225D1/de
Publication of DE69833225T2 publication Critical patent/DE69833225T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ladders (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Road Signs Or Road Markings (AREA)
  • Saccharide Compounds (AREA)
DE69833225T 1997-11-13 1998-11-10 Verwendung von histamin um die blutkonzentration des histamins zu erhöhen Expired - Fee Related DE69833225T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/969,384 US6071942A (en) 1996-05-14 1997-11-13 Elevation of circulating blood histamine levels
US969384 1997-11-13
PCT/US1998/023956 WO1999025341A1 (en) 1997-11-13 1998-11-10 Use of histamine for elevating blood histamine levels

Publications (2)

Publication Number Publication Date
DE69833225D1 true DE69833225D1 (de) 2006-04-06
DE69833225T2 DE69833225T2 (de) 2006-08-10

Family

ID=25515502

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833225T Expired - Fee Related DE69833225T2 (de) 1997-11-13 1998-11-10 Verwendung von histamin um die blutkonzentration des histamins zu erhöhen

Country Status (15)

Country Link
US (2) US6071942A (de)
EP (1) EP1047422B1 (de)
JP (1) JP2001522885A (de)
KR (1) KR20010031979A (de)
CN (1) CN1128618C (de)
AT (1) ATE315393T1 (de)
AU (1) AU760068B2 (de)
CA (1) CA2310255A1 (de)
DE (1) DE69833225T2 (de)
DK (1) DK1047422T3 (de)
ES (1) ES2256971T3 (de)
HK (1) HK1035330A1 (de)
IL (1) IL135872A0 (de)
PT (1) PT1047422E (de)
WO (1) WO1999025341A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
WO2000074649A2 (en) * 1999-06-03 2000-12-14 Maxim Pharmaceuticals, Inc. Ophthalmic histamine compositions and uses thereof
US20030091553A1 (en) * 2001-10-19 2003-05-15 Gehlsen Kurt R. Use of histamine to treat liver disease
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
JP2008511553A (ja) * 2004-09-03 2008-04-17 プロメティック バイオサイエンシズ インコーポレーテッド 免疫調節活性および化学防護活性を有する置換型プリニル誘導体ならびにその単独使用または中鎖長の脂肪酸もしくはグリセリドとの併用
US9023881B2 (en) 2012-12-05 2015-05-05 Biohealthonomics Inc. Methods for restoration of histamine balance
CA2893438A1 (en) * 2012-12-05 2014-06-12 Biohealthonomics Inc. Methods for restoration of histamine balance
WO2015058040A1 (en) * 2013-10-17 2015-04-23 Grant Labs, Inc. Suppression of cellular transformation and dysplasia by topical application of lefty

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1911429A1 (de) * 1969-03-06 1970-09-24 Waldhof Zellstoff Fab Lipophile Puryl-(6)-histaminderivate und Verfahren zu ihrer Herstellung
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
EP0493468B1 (de) * 1989-09-19 1996-04-17 Syntello Inc Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
US5135491A (en) * 1990-11-02 1992-08-04 Baldwin Brian E Patient controlled infusion apparatus and method
EP0642333B1 (de) * 1992-04-22 1998-06-24 Molecular Rx., Inc. Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
JPH07165582A (ja) * 1993-12-08 1995-06-27 Seiji Takayama 免疫抗癌剤の抗癌効果増強剤
US5478211A (en) * 1994-03-09 1995-12-26 Baxter International Inc. Ambulatory infusion pump
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels

Also Published As

Publication number Publication date
JP2001522885A (ja) 2001-11-20
EP1047422A1 (de) 2000-11-02
ATE315393T1 (de) 2006-02-15
DE69833225T2 (de) 2006-08-10
US6071942A (en) 2000-06-06
CA2310255A1 (en) 1999-05-27
ES2256971T3 (es) 2006-07-16
AU1395599A (en) 1999-06-07
PT1047422E (pt) 2006-05-31
CN1285744A (zh) 2001-02-28
CN1128618C (zh) 2003-11-26
EP1047422B1 (de) 2006-01-11
AU760068B2 (en) 2003-05-08
KR20010031979A (ko) 2001-04-16
IL135872A0 (en) 2001-05-20
WO1999025341A1 (en) 1999-05-27
DK1047422T3 (da) 2006-04-18
US6613788B1 (en) 2003-09-02
HK1035330A1 (en) 2001-11-23

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
MX9601150A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.
ATE183087T1 (de) Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
ATE419875T1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
ATE315393T1 (de) Verwendung von histamin um die blutkonzentration des histamins zu erhöhen
WO1997042968A3 (en) Administration of histamine for therapeutic purposes
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
UA85548C2 (ru) Применение водного экстракта листьев красного винограда для предупреждения перехода от клинически незначительных ранних стадий хронической венозной недостаточности к i, ii или iii стадии
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
Ranque et al. Decreased prevalence and intensity of Loa loa infection in a community treated with ivermectin every three months for two years
DK1137420T3 (da) Anvendelse af en kombination af et purin og en nitrogenmonooxiddonor til forebyggelse eller behandling af sexuel dysfunktion
DE69735722D1 (de) D-methionin zur reduzierung der toxizität von platin-enthaltenden antitumor verbindungen
SE0101328D0 (sv) Therapeutic treatment
GB9903091D0 (en) Therapeutic nucleoside compound
Ranque et al. IShort Report1
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee